Enzymatic conversion of aclacinomycin A to Y by a specific oxidoreductase in Streptomyces. 1979

A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa

A specific oxidoreductase converting aclacinomycin A to a new analog, aclacinomycin Y, was purified to apparent homogeneity from the culture filtrate of aclacinomycin-producing microorganisms. The isolated enzyme was a weakly acidic protein (isoelectric point, 5.9) with a molecular weight of about 72,000. The enzymatic reaction requires molecular oxygen and has a pH optimum at 5.5. The enzyme catalyzed an oxidation of the terminal sugar, L-cinerulose, of the trisaccharide moiety of aclacinomycin A to L-aculose (2,3,6-trideoxyhex-2-enopyranos-4-ulose) with removal of two electrons. Studies of substrate specificity revealed that the enzyme is an oxidoreductase capable of modifying anthracyclic triglycosides by oxidizing their terminal sugars.

UI MeSH Term Description Entries
D009279 Naphthacenes Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES. Tetracenes,Benz(b)Anthracenes
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013302 Streptomyces A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.
D015250 Aclarubicin An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity. Aclacinomycin A,Aclacin,Aclaplastin,MA-144A1,NSC-208734,MA 144A1,MA144A1,NSC 208734,NSC208734

Related Publications

A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
November 1983, The Journal of antibiotics,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
June 1974, Archives of biochemistry and biophysics,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
July 2000, Biochimica et biophysica acta,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
January 2003, Communications in agricultural and applied biological sciences,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
June 1992, The Journal of antibiotics,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
October 1998, Applied and environmental microbiology,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
May 1996, Bioscience, biotechnology, and biochemistry,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
February 2007, Acta crystallographica. Section D, Biological crystallography,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
January 2022, Biochemical and biophysical research communications,
A Yoshimoto, and T Ogasawara, and I Kitamura, and T Oki, and T Inui, and T Takeuchi, and H Umezawa
August 1997, Biochemical Society transactions,
Copied contents to your clipboard!